We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+13.54%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$5.12B
AUM Growth
-$493M
Cap. Flow
-$785M
Cap. Flow %
-15.35%
Top 10 Hldgs %
51.39%
Holding
136
New
20
Increased
23
Reduced
33
Closed
42

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$101M
2
RLAY icon
Relay Therapeutics
RLAY
+$70.2M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$59.9M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$39.8M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$33.2M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$122M
2
ACLX
Arcellx
ACLX
+$95.6M
3
BSX icon
Boston Scientific
BSX
+$93.3M
4
FOLD
Amicus Therapeutics
FOLD
+$90.7M
5
ATXS
Astria Therapeutics
ATXS
+$84.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCUL icon
76
CALL
Ocular Therapeutix
OCUL
$2.01B
$4.24M 0.08%
+500,000
New +$4.77M
ADMA icon
77
ADMA Biologics
ADMA
$2.04B
$4.21M 0.08%
467,233
-416,235
-47% -$6.57M
IKT icon
78
Inhibikase Therapeutics
IKT
$316M
$3.89M 0.08%
2,315,000
-3,106,568
-57% -$5.52M
CBIO
79
Crescent Biopharma
CBIO
$417M
$3.8M 0.07%
206,942
-246,744
-54% -$2.83M
APLS
80
DELISTED
Apellis Pharmaceuticals
APLS
$3.26M 0.06%
+80,956
New +$1.74M
OM icon
81
Outset Medical
OM
$80.8M
$3.2M 0.06%
833,333
– –
EDSA icon
82
Edesa Biotech
EDSA
$64.7M
$2.95M 0.06%
+563,239
New +$1.69M
ADPT icon
83
Adaptive Biotechnologies
ADPT
$3.54B
$2.12M 0.04%
+152,500
New +$2.43M
AVTX icon
84
Avalo Therapeutics
AVTX
$940M
$2.09M 0.04%
139,667
– –
CNTB
85
Connect Biopharma Holdings
CNTB
$147M
$2.08M 0.04%
792,696
– –
CORT icon
86
Corcept Therapeutics
CORT
$9.63B
$2.02M 0.04%
+50,000
New +$1.87M
MDLN
87
Medline Inc
MDLN
$34.8B
$1.25M 0.02%
28,000
– –
PTN
88
Palatin Technologies
PTN
$15.1M
$1.08M 0.02%
61,945
-8,055
-12% -$153K
CPIX icon
89
Cumberland Pharmaceuticals
CPIX
$115M
$640K 0.01%
196,978
-144,109
-42% -$555K
RVMDW icon
90
Revolution Medicines Inc Warrant
RVMDW
$102M
$448K 0.01%
250,000
– –
XGN icon
91
Exagen
XGN
$103M
$345K 0.01%
+114,893
New +$444K
ENSC icon
92
Ensysce Biosciences
ENSC
$4.26M
$46.7K ﹤0.01%
86,666
– –
SRZNW icon
93
Surrozen Inc Warrant
SRZNW
$2.67K ﹤0.01%
166,666
– –
ACLX
94
DELISTED
Arcellx
ACLX
– –
-1,466,071
Closed -$95.6M
ALDX icon
95
Aldeyra Therapeutics
ALDX
$104M
– –
-4,185,632
Closed -$21.7M
AQST icon
96
Aquestive Therapeutics
AQST
$494M
– –
-747,193
Closed -$4.83M
ATXS
97
DELISTED
Astria Therapeutics
ATXS
– –
-6,485,420
Closed -$84.9M
BDSX icon
98
Biodesix
BDSX
$207M
– –
-108,694
Closed -$739K
BHVN icon
99
CALL
Biohaven
BHVN
$2.13B
– –
-500,000
Closed -$5.64M
BIIB icon
100
Biogen
BIIB
$30.8B
– –
-124,000
Closed -$21.8M
2 3
4
5 6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Perceptive Advisors held 136 positions worth $5.12B, down 8.8% from $5.61B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors withdrew a net $785M in Q1 2026, closing 42 positions and reducing 33 holdings. Its most notable exit was Exact Sciences, an estimated $122M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier.

Against the trend, Perceptive Advisors opened a new position in Ionis Pharmaceuticals worth $37.8M.

  • Perceptive Advisors's largest Q1 2026 buy was Ionis Pharmaceuticals: 504,000 shares worth $37.8M.
  • Perceptive Advisors added most to Ascendis Pharma A/S in Q1 2026, an estimated $101M increase.
  • Perceptive Advisors's biggest Q1 2026 reduction was Apogee Therapeutics, cutting an estimated $57.4M.
  • Perceptive Advisors fully exited Exact Sciences in Q1 2026, selling an estimated $122M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $5.12B portfolio in Q1 2026.
  • Perceptive Advisors opened 20 new positions and closed 42 in Q1 2026.
  • Perceptive Advisors's portfolio value fell 8.8% quarter-over-quarter to $5.12B.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.